|
Summary
February 2008, Vol. 17, No. 2, Pages 209-215
, DOI 10.1517/13543784.17.2.209
An update on huperzine A as a treatment for Alzheimer's diseaseJohn T Little1Georgetown University Hospital, Department of Psychiatry, 3800 Reservoir Road, NW, Kober-Cogan 604, Washington, DC 20007, USA +1 202 687 1761; +1 202 687 6658; jtl106@gunet.georgetown.edu 2University College Hospital Galway, Older Adult Mental Health Services, Galway, Ireland 3Georgetown University Hospital, Department of Neurology, Washington, DC, USA Huperzine A is a natural cholinesterase inhibitor derived from the Chinese herb Huperzia serrata. There is evidence that huperzine A may compare favorably in symptomatic efficacy to cholinesterase inhibitors in use. In addition, huperzine A has antioxidant and neuroprotective properties that suggest that it may be useful as a disease-modifying treatment for Alzheimer's disease (AD). The drug is available as a nutriceutical in the US. However, there have been no published controlled clinical trials outside China assessing its toxicity and efficacy. This paper reviews the development of huperzine A as a treatment for AD, including the Phase II trial now under way in the US. Forward Links to Citing ArticlesBai-song Wang, Hao Wang, Zhao-hui Wei, Yan-yan Song, Lu Zhang, Hong-zhuan Chen. (2009) Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer’s disease: an updated meta-analysis. Journal of Neural Transmission 116:4, 457-465 Online publication date: 1-May-2009. CrossRef (2008) Current awareness in geriatric psychiatry. International Journal of Geriatric Psychiatry 23:9, i-viii Online publication date: 1-Oct-2008. CrossRef Users who read this article also read:
|
|





Author for correspondence
TOC Alert